November 2019 Volume 15, Issue 11
Volume 15, Issue 11 | November 2019
November 2019
In this Issue
Clinical Trials
Reata’s omav shows its MOXIe
Investigational treatment for Friedreich’s ataxia leads to significant improvement in patient scoresDynamic progress for diabetes
Two companies are making large strides in the diabetes realmRiding the waves of Lonsurf
Taiho Oncology reports promising findings for patients with prior gastrectomyA new idea with IDO
Phase 2 trial evaluates a new tool in pediatric cancer immunotherapyDiagnostics
Prostates and PARPs
Theragnostics makes moves on the prostate frontTransformative technology
Mount Sinai establishes institute for research and trainingBetting on the future
Illumina, QIAGEN look to stake their claim on the NGS IVD marketAdvancing nuclear medicine to treat cancer
Fuzionaire Diagnostics partners with Japan Medical Isotope Technology Development to launch new firmBusiness & Government Policy
It’s all in the delivery
Checking out the news in drug delivery advancementsPassing some gems to Emerald
Amarantus enters into agreement to license diverse therapeutics portfolio to CBD-focused companyOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsPushing the envelope
Duke launches center to explore innovative science and technology policyMajor option for microinjector
Clearside announces option exercise by REGENXBIO for gene therapy delivery techPatent Docs: Sovereign immunity not absolute for states under the Eleventh Amendment
Kevin Noonan discusses a case in which the University of Texas sued Boston Scientific for patent infringement related to implantable drug-releasing biodegradable fibersEditor's Focus
Editor’s Focus: Organic is often good for you
It seems there might be a trend away from crude and opportunistic tack-on merger and acquisition deals and toward more deliberate M&A deals that better fit companies' current and future needs, which would be welcome in an era when internal, organic R&D growth isn't what it used to beFeature
2019 ASCB|EMBO Show Preview: A biologically dynamic duo
Year three of the collaborative ASCB|EMBO meeting presents a wide variety of innovative cell biology researchCommentary
Guest Commentary: Realizing the promise of microelectrode arrays
Improving throughput and reliability in routine neurotoxicity testingOut of order: Not to be negative
The very fact that we define results as positive or negative highlights our reluctance to accept change, that the story we have built in our heads may not fully reflect our realityResearch & Development
Untangling the knot
USC researchers publish results in Cell Stem Cell that could prove the key to effective, reproducible cell reprogrammingStanford on the mind
University teams make progress on rare CNS disease and identify a potential Parkinson’s biomarkerImproving the innovation lifecycle
CAS launches Formulus in effort to help fast-track product developmentCalculating the risk
Elsevier and pharma industry leaders to build new drug-drug interaction risk calculatorContract Services
Gaining ground
QPS announces new clinics in three key areas for CRO market growthThey can’t ‘contain’ themselves
Burgeoning oncology pipeline increases demand for containment manufacturing, which is good news for many CMOsGlobal workforce challenges for CROs
VIARES partners with ACRP to help address these issuesDiscovery
Building off of nature’s basics
New antibacterial tactic harnesses natural enzymes to kill bacteriaA mutual microbiome plan
Kaleido Biosciences collaborates with Gustave Roussy to develop Microbiome Metabolic TherapiesEmulating diabetes for drug discovery
Collaboration will develop three-dimensional modelsNew target for two tricky cancers
Blocking a specific protein reduces fibrosis and thwarts ovarian and pancreatic cancerPreclinical
Auransa advances AU-409
Company presents new preclinical data on its potential treatment for hepatocellular carcinomaJoining hands on first-in-class cancer therapy
Ivy Brain Tumor Center and Salarius conduct preclinical study to test seclidemstatRepurposed receptor
Drug is said to reduce pulmonary fibrosis by 56 percentBiocon in-licenses early-stage biosimilar from Evotec
Company will undertake development, manufacturing and commercialization under its own label
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Overcoming barriers in gene therapy
Advanced gene editing, delivery, and analytical tools are driving better gene therapies.
A multiomic approach to profiling brain tumors
Probing the molecular drivers of brain metastasis reveals novel therapeutic targets.
Enhancing immune cell profiling with digital technologies
Software innovations help researchers decode immune complexity in cancer.
